首頁(yè) > SCI期刊 > 醫(yī)學(xué)期刊 > 中科院2區(qū) > SCIE期刊 > Biomedicine & Pharmacotherapy(非官網(wǎng))

          Biomedicine & Pharmacotherapy SCIE

          國(guó)際簡(jiǎn)稱:BIOMED PHARMACOTHER  參考譯名:生物醫(yī)學(xué)與藥物治療

          主要研究方向:醫(yī)學(xué)-藥學(xué)  預(yù)警期刊  審稿周期: 約2月 約7周

          《生物醫(yī)學(xué)與藥物治療》(Biomedicine & Pharmacotherapy)是一本由Elsevier Masson出版的以醫(yī)學(xué)-藥學(xué)為研究特色的國(guó)際期刊,發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章,及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn),旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開(kāi)放期刊。該期刊享有很高的科學(xué)聲譽(yù),影響因子不斷增加,發(fā)行量也同樣高。

          • 2區(qū) 中科院分區(qū)
          • Q1 JCR分區(qū)
          • 1743 年發(fā)文量
          • 6.9 IF影響因子
          • 未開(kāi)放 是否OA
          • 78 H-index
          • 1982 創(chuàng)刊年份
          • Monthly 出版周期
          • Multi-Language 出版語(yǔ)言

          Biomedicine & Pharmacotherapy is a multidisciplinary journal which publishes full-length, original research reports, reviews, and preliminary communications or letters to the editor which fall within the general scope of clinical and basic medicine and pharmacology.

          The general fields of interest will include Cancer, Nutriceutics, Neurodegenerative, Cardiac and Infectious Diseases.

          Special emphasis will be placed on studies of specific topics such as molecular mechanisms, gene regulation in normal and pathologic cells as well as susceptibility in response to oncogenic agents. Effects of drugs on preclinical and clinical pharmacology and the role of bacteria, viruses and parasites in animals and humans.

          Brief reports of meetings, symposia and conferences will also be considered for publication as well as brief listings of scientific meetings or academic courses of interest to the readers

          [ 查看全部 ]

          Biomedicine & Pharmacotherapy期刊信息

          • ISSN:0753-3322
          • 出版語(yǔ)言:Multi-Language
          • 是否OA:未開(kāi)放
          • E-ISSN:1950-6007
          • 出版地區(qū):FRANCE
          • 是否預(yù)警:
          • 出版商:Elsevier Masson
          • 出版周期:Monthly
          • 創(chuàng)刊時(shí)間:1982
          • 開(kāi)源占比:0.9507
          • Gold OA文章占比:96.76%
          • OA被引用占比:0.5432...
          • 出版國(guó)人文章占比:0.56
          • 出版撤稿占比:0.0061...
          • 研究類(lèi)文章占比:67.58%

          Biomedicine & Pharmacotherapy CiteScore評(píng)價(jià)數(shù)據(jù)(2024年最新版)

          CiteScore SJR SNIP CiteScore 指數(shù)
          11.9 1.493 1.409
          學(xué)科類(lèi)別 分區(qū) 排名 百分位
          大類(lèi):Pharmacology, Toxicology and Pharmaceutics 小類(lèi):Pharmacology Q1 28 / 313

          91%

          名詞解釋?zhuān)?/b>CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù),是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年(含計(jì)算年度)的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如,2022年的 CiteScore 計(jì)算方法為:2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量 注:文獻(xiàn)類(lèi)型包括:文章、評(píng)論、會(huì)議論文、書(shū)籍章節(jié)和數(shù)據(jù)論文。

          Biomedicine & Pharmacotherapy中科院評(píng)價(jià)數(shù)據(jù)

          中科院 2023年12月升級(jí)版

          Top期刊 綜述期刊 大類(lèi)學(xué)科 小類(lèi)學(xué)科
          醫(yī)學(xué) 2區(qū) PHARMACOLOGY & PHARMACY 藥學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué):研究與實(shí)驗(yàn) 1區(qū) 2區(qū)

          中科院 2022年12月升級(jí)版

          Top期刊 綜述期刊 大類(lèi)學(xué)科 小類(lèi)學(xué)科
          醫(yī)學(xué) 2區(qū) PHARMACOLOGY & PHARMACY 藥學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué):研究與實(shí)驗(yàn) 1區(qū) 2區(qū)

          中科院 2021年12月舊的升級(jí)版

          Top期刊 綜述期刊 大類(lèi)學(xué)科 小類(lèi)學(xué)科
          醫(yī)學(xué) 2區(qū) PHARMACOLOGY & PHARMACY 藥學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué):研究與實(shí)驗(yàn) 1區(qū) 2區(qū)

          中科院 2021年12月基礎(chǔ)版

          Top期刊 綜述期刊 大類(lèi)學(xué)科 小類(lèi)學(xué)科
          醫(yī)學(xué) 2區(qū) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué):研究與實(shí)驗(yàn) PHARMACOLOGY & PHARMACY 藥學(xué) 3區(qū) 2區(qū)

          中科院 2021年12月升級(jí)版

          Top期刊 綜述期刊 大類(lèi)學(xué)科 小類(lèi)學(xué)科
          醫(yī)學(xué) 2區(qū) PHARMACOLOGY & PHARMACY 藥學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué):研究與實(shí)驗(yàn) 1區(qū) 2區(qū)

          中科院 2020年12月舊的升級(jí)版

          Top期刊 綜述期刊 大類(lèi)學(xué)科 小類(lèi)學(xué)科
          醫(yī)學(xué) 2區(qū) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué):研究與實(shí)驗(yàn) PHARMACOLOGY & PHARMACY 藥學(xué) 2區(qū) 2區(qū)

          Biomedicine & Pharmacotherapy JCR評(píng)價(jià)數(shù)據(jù)(2023-2024年最新版)

          按JIF指標(biāo)學(xué)科分區(qū) 收錄子集 分區(qū) 排名 百分位
          學(xué)科:MEDICINE, RESEARCH & EXPERIMENTAL SCIE Q1 21 / 189

          89.2%

          學(xué)科:PHARMACOLOGY & PHARMACY SCIE Q1 15 / 354

          95.9%

          按JCI指標(biāo)學(xué)科分區(qū) 收錄子集 分區(qū) 排名 百分位
          學(xué)科:MEDICINE, RESEARCH & EXPERIMENTAL SCIE Q1 18 / 189

          90.74%

          學(xué)科:PHARMACOLOGY & PHARMACY SCIE Q1 25 / 354

          93.08%

          Biomedicine & Pharmacotherapy歷年數(shù)據(jù)統(tǒng)計(jì)

          影響因子
          中科院分區(qū)

          Biomedicine & Pharmacotherapy中國(guó)學(xué)者發(fā)文選摘

          • 1、Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+T cell-dependent immune response

            Author: Liu, Jing; Hu, Yan-Yan; Zhang, Qiu-Yan; Zhang, Ya-Nan; Li, Na; Zhang, Zhe-Rui; Zhan, Shun-Li; Gao, Lei; Deng, Cheng-Lin; Li, Xiao-Dan; Yuan, Shao-Peng; He, Yuan-Qiao; Ye, Han-Qing; Zhang, Bo

            Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114094

          • 2、Glutathione improves testicular spermatogenesis through inhibiting oxidative stress, mitochondrial damage, and apoptosis induced by copper deposition in mice with Wilson disease

            Author: Chen, Kuiyu; Wu, Limin; Liu, Qianzhuo; Tan, Fang; Wang, Luyao; Zhao, Dan; Fang, Xinru; Liu, Xiang; Liu, Jiabo; Han, Hui

            Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114107

          • 3、Arctium lappa (Burdock): Insights from ethnopharmacology potential, chemical constituents, clinical studies, pharmacological utility and nanomedicine

            Author: Yosri, Nermeen; Alsharif, Sultan M.; Xiao, Jianbo; Musharraf, Syed G.; Zhao, Chao; Saeed, Aamer; Gao, Ruichang; Said, Noha S.; Di Minno, Alessandro; Daglia, Maria; Guo, Zhiming; Khalifa, Shaden A. M.; El-Seedi, Hesham R.

            Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114104

          • 4、A novel inhibitor of PGK1 suppresses the aerobic glycolysis and proliferation of hepatocellular carcinoma

            Author: Li, Mingfeng; Zhang, Aotong; Qi, Xin; Yu, Rilei; Li, Jing

            Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114115

          • 5、Sodium tanshinone IIA sulfonate protects against hyperhomocysteine-induced vascular endothelial injury via activation of NNMT/SIRT1-mediated NRF2/HO-1 and AKT/MAPKs signaling in human umbilical vascular endothelial cells

            Author: Zhou, Zhong-Yan; Shi, Wen-Ting; Zhang, Jing; Zhao, Wai-Rong; Xiao, Ying; Zhang, Kai-Yu; Ma, Jie; Tang, Jing-Yi; Wang, Yu

            Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114137

          • 6、Attenuation of hyperglycemia-associated dyslipidemic, oxidative, cognitive, and inflammatory crises via modulation of neuronal ChEs/NF-kappa B/COX-2/NOx, and hepatorenal functional deficits by the Tridax procumbens extract

            Author: Hogan, Itam Ako; Kuo, Yu-Cheng; Abubakar, Asmau N.; Lawal, Bashir; Agboola, Abdulhakeem R.; Lukman, Halimat Yusuf; Onikanni, Sunday Amos; Olawale, Femi; Fadaka, Adewale Oluwaseun; Ibrahim, Yunusa O.; Babalola, Shukurat B.; Batiha, Gaber El -Saber; Albogami, Sarah M.; Alorabi, Mohammed; De Waard, Michel; Huang, Hsu-Shan

            Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114114

          • 7、Exercise induced meteorin-like protects chondrocytes against inflammation and pyroptosis in osteoarthritis by inhibiting PI3K/Akt/NF-kappa B and NLRP3/caspase-1/GSDMD signaling

            Author: Liu, Jiabao; Jia, Shuangshuo; Yang, Yue; Piao, Longhuan; Wang, Ziyuan; Jin, Zhuangzhuang; Bai, Lunhao

            Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114118

          • 8、Revealment study on the regulation of lipid metabolism by Lingguizhugan Decoction in heart failure treatment based on integrated lipidomics and proteomics

            Author: Wang, Xu; Gao, Yanhua; Zhang, Jia; Zhang, Huaxing; Sun, Shuo; Su, Suwen; Kong, Dezhi; Wang, Qiao

            Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114066

          免責(zé)聲明

          若用戶需要出版服務(wù),請(qǐng)聯(lián)系出版商:ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 23 RUE LINOIS, PARIS, FRANCE, 75724。